Abivax SA Sponsored ADR (NASDAQ:ABVX - Get Free Report) shares saw unusually-strong trading volume on Tuesday . Approximately 180,769 shares traded hands during mid-day trading, an increase of 2% from the previous session's volume of 176,763 shares.The stock last traded at $9.00 and had previously closed at $8.83.
Wall Street Analyst Weigh In
Several analysts have recently commented on ABVX shares. JMP Securities reiterated a "market outperform" rating and issued a $33.00 price target on shares of Abivax in a research report on Wednesday, April 30th. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 price target on shares of Abivax in a research report on Thursday, March 20th.
Read Our Latest Stock Analysis on Abivax
Abivax Trading Up 11.6%
The stock's 50-day moving average is $6.94 and its 200-day moving average is $6.74. The company has a debt-to-equity ratio of 1.29, a quick ratio of 1.25 and a current ratio of 1.25.
Institutional Trading of Abivax
Hedge funds have recently bought and sold shares of the company. Bank of America Corp DE boosted its position in Abivax by 56.1% during the fourth quarter. Bank of America Corp DE now owns 5,536 shares of the company's stock worth $41,000 after acquiring an additional 1,990 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Abivax by 34.3% during the first quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company's stock worth $63,000 after acquiring an additional 2,595 shares during the last quarter. Ameriprise Financial Inc. acquired a new stake in Abivax during the fourth quarter worth approximately $85,000. Guggenheim Capital LLC acquired a new stake in Abivax during the fourth quarter worth approximately $92,000. Finally, Stonepine Capital Management LLC acquired a new stake in Abivax during the fourth quarter worth approximately $110,000. Institutional investors and hedge funds own 47.91% of the company's stock.
About Abivax
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
Read More
Before you consider Abivax, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abivax wasn't on the list.
While Abivax currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
